en Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="color: black;"><span lang="en-US" style="font-family: Calibri; font-size: 9pt;"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background</span></span></span></span></span></span><span lang="en-US" style="font-family: Calibri; font-size: 9pt;"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-family: Calibri; font-size: 9pt;"><span style="font-family:Calibri"><span style="language:en-US">transcatheter arterial chemoembolization (TACE) is the standard treatment for advanced and unresectable hepatocellular carcinoma (HCC) patients. Lenvatinib (LVTN) is one of the novel oral antiangiogenic drugs demonstrating promising application prospects, which has been widely concerned and studied. This work was to systematically analyze efficacy and safety of TCAE combined with LVTN plus radiotherapy (RT) on HCC through the meta-analysis. </span></span></span><span lang="en-US" style="font-family: Calibri; font-size: 9pt;"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Materials and Methods: </span></span></span></span></span></span><span lang="en-US" style="font-family: Calibri; font-size: 9pt;"><span style="font-family:Calibri"><span style="language:en-US">a comprehensive search was conducted on PubMed, Web of Science, Embase, and The Cochrane Library databases from January 2000 to the present to identify studies examining the effectiveness and safety of combining TCAE with LVTN and RT for the treatment of HCC. Relevant literature was screened, and essential information along with evaluation indicators were extracted for analysis. RevMan5.3 was employed for quality assessment and meta-analysis of the included studies, and forest maps (FMs) were drawn. </span></span></span><span lang="en-US" style="font-family: Calibri; font-size: 9pt;"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Results: </span></span></span></span></span></span><span lang="en-US" style="font-family: Calibri; font-size: 9pt;"><span style="font-family:Calibri"><span style="language:en-US">five studies were included. Meta-analysis showed that TCAE combined with LVTN plus RT enhanced the total objective response rate (ORR) of HCC (OR = 3.16, 95%CI = 1.37-7.32, P < 0.05). TCAE combined with LVTN plus RT enhanced the total survival (OS) rate of HCC patients (OR = 2.01, 95%CI=1.30-3.12, P < 0.05). TCAE combined with LVTN plus RT could reduce the diarrhea rate greatly (OR = 2.84, 95%CI = 1.16-6.96, P< 0.05). However, no observable difference was found in the incidence of hypertension caused by TCAE combined with LVTN plus RT (OR = 2.39, 95%CI = 0.62-9.23, P > 0.05). </span></span></span><span lang="en-US" style="font-family: Calibri; font-size: 9pt;"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Conclusion: </span></span></span></span></span></span><span lang="en-US" style="font-size: 9pt;"><font face="Calibri">LVTN combined with TACE had superior efficacy on HCC compared with non-LVTN combined with TCAE, but the related side effects (SEs) may affect the scope of application and the quality of life of patients.</font></span></span></span></span></span></span></div> lenvatinib, chemoembolization, hepatocellular, treatment outcome, meta-analysis. 947 954 http://ijrr.com/browse.php?a_code=A-10-1-1262&slc_lang=en&sid=1 X. Wang fengshijia18@163.com 7900319475328460028624 7900319475328460028624 Yes Department of Intervention, Xinchang County People's Hospital, Shaoxing 312500, Zhejiang Province, China X. Xie 7900319475328460028625 7900319475328460028625 No Department of Intervention, Xinchang County People's Hospital, Shaoxing 312500, Zhejiang Province, China G. Zhang 7900319475328460028626 7900319475328460028626 No Department of Intervention, Xinchang County People's Hospital, Shaoxing 312500, Zhejiang Province, China B. Wang 7900319475328460028627 7900319475328460028627 No Department of Intervention, Xinchang County People's Hospital, Shaoxing 312500, Zhejiang Province, China